Do you have a question about our COVID-19 vaccine candidate?
Vaccines are developed many different ways, all of which use a non-infectious version of a virus or disease antigen intended to trigger an immune response to a virus or disease. The body is then conditioned to defend itself against encounters with the virus or disease.
In the plant-based vaccine development process, living plants are used as bioreactors to produce a non-infectious particle that mimics the target virus. This is all done without the use of any live viruses.
Our plant-based vaccine platform is versatile, designed to produce both vaccines and antibodies – with a combination of speed, accuracy, and adaptability that is designed to produce safe and efficacious vaccines and therapies that can be used to rapidly respond to emerging pandemics or global needs.
Once a virus has been genetically sequenced, Medicago uses its Proficia® technology to synthesize the virus’s code so that its genetic instructions can be “read” by plants.
The Proficia® technology developed by Medicago is unique. It uses Nicotiana benthamiana plants, which is the most widely used experimental host in plant virology, due mainly to the large number of viruses that can successfully infect it. The natural cell process of Nicotiana benthamiana is therefore temporarily exploited to produce virus-like particles (VLPs).
i Vaccines Europe . How are vaccines produced?. Consulté en septembre 2021.
ii Bally, J et al. Nature Plants. The extremophile Nicotiana benthamiana has traded viral defence for early vigour. Consulté en septembre 2021.